GR3031985T3 - Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression - Google Patents

Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression

Info

Publication number
GR3031985T3
GR3031985T3 GR990403078T GR990403078T GR3031985T3 GR 3031985 T3 GR3031985 T3 GR 3031985T3 GR 990403078 T GR990403078 T GR 990403078T GR 990403078 T GR990403078 T GR 990403078T GR 3031985 T3 GR3031985 T3 GR 3031985T3
Authority
GR
Greece
Prior art keywords
antimessenger
urokinase receptor
pct
oligonucleotides
reversion
Prior art date
Application number
GR990403078T
Other languages
English (en)
Inventor
Sergio Capaccioli
Rosso Mario Del
Gabriella Fibbi
Alessandro Quattrone
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Publication of GR3031985T3 publication Critical patent/GR3031985T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
GR990403078T 1994-07-22 1999-11-29 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression GR3031985T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI941560A IT1271684B (it) 1994-07-22 1994-07-22 Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
PCT/EP1995/002793 WO1996003414A1 (en) 1994-07-22 1995-07-17 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression

Publications (1)

Publication Number Publication Date
GR3031985T3 true GR3031985T3 (en) 2000-03-31

Family

ID=11369344

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990403078T GR3031985T3 (en) 1994-07-22 1999-11-29 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression

Country Status (11)

Country Link
US (1) US5872106A (el)
EP (1) EP0772620B1 (el)
JP (1) JP3687919B2 (el)
AT (1) ATE185144T1 (el)
AU (1) AU3112395A (el)
DE (1) DE69512522T2 (el)
DK (1) DK0772620T3 (el)
ES (1) ES2136868T3 (el)
GR (1) GR3031985T3 (el)
IT (1) IT1271684B (el)
WO (1) WO1996003414A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
AU2197600A (en) * 1998-12-30 2000-07-24 Oligos Etc. Inc. Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
WO2005016374A1 (en) * 2003-07-02 2005-02-24 Board Of Regents, The University Of Texas System Regulation of urokinase receptor expression by phosphoglycerate kinase
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0467932B1 (en) * 1989-04-07 2000-10-18 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor

Also Published As

Publication number Publication date
JPH10502823A (ja) 1998-03-17
EP0772620A1 (en) 1997-05-14
ITMI941560A1 (it) 1996-01-22
EP0772620B1 (en) 1999-09-29
US5872106A (en) 1999-02-16
IT1271684B (it) 1997-06-04
WO1996003414A1 (en) 1996-02-08
ATE185144T1 (de) 1999-10-15
DK0772620T3 (da) 2000-03-27
ITMI941560A0 (it) 1994-07-22
DE69512522D1 (de) 1999-11-04
JP3687919B2 (ja) 2005-08-24
ES2136868T3 (es) 1999-12-01
DE69512522T2 (de) 2000-01-13
AU3112395A (en) 1996-02-22

Similar Documents

Publication Publication Date Title
NO952229D0 (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
IL135836A0 (en) Substituted anilides
BG104679A (en) The use of fumaric acid derivatives in transplant medicine
BR9405707A (pt) Inibiçao anti-sentido de c-myc para modular a proliferaçao de células de músculo liso
GR3020975T3 (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes.
BR9808647A (pt) Inibição de ìntron anti-sentido de enzima de expressão de ramificação de amido
PL333429A1 (en) Benzonaphtyridines useful in particular in treating bronchial diseases
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
PT716611E (pt) Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo
GR3031985T3 (en) Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression
AU5818394A (en) Use of prodelphinidines for treating arthrosis
MXPA02000296A (es) Compuestos parecidos a aminoceramida y metodos de uso.
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation
PL322847A1 (en) Condensed b-carbolins